NCT06921980 Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
| NCT ID | NCT06921980 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | CAR T-cell Therapy |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-02-25 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior. Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of AIHA * Subjects will receive cell therapy such as CAR T-cell therapy * Male or female, aged 18-65 years * Willing and able to comply with the requirements for this study and written informed consent Exclusion Criteria: * History of psychiatric illness * History of severe brain disease * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06921980 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying CAR T-cell Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06921980 currently recruiting?
Yes, NCT06921980 is actively recruiting participants. Contact the research team at kuangzhexiang@ihcams.ac.cn for enrollment information.
Where is the NCT06921980 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06921980 clinical trial?
NCT06921980 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 20 participants.